Cogent Biosciences, Inc.
COGT
Kedudukan dalam Saham
#3334
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Harga Saham
$30.11
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.22B
Perubahan (1 hari)
2.00%
Perubahan (1 tahun)
85.64%
Negara
US
Perdagangan Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Pendapatan untuk Cogent Biosciences, Inc. (COGT)
Pendapatan pada Jun 2026 TTM: $-377.18M
Menurut laporan kewangan terkini Cogent Biosciences, Inc., pendapatan semasa syarikat ialah $-377.18M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-192.41M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-140.24M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Cogent Biosciences, Inc. dari 2015 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-377.18M | 47.42% |
| 2024 | $-255.86M | 32.98% |
| 2023 | $-192.41M | 37.20% |
| 2022 | $-140.24M | 94.04% |
| 2021 | $-72.27M | -3.39% |
| 2020 | $-74.81M | 135.00% |
| 2019 | $-31.83M | -7.82% |
| 2018 | $-34.53M | 35.46% |
| 2017 | $-25.49M | 40.65% |
| 2016 | $-18.12M | 174.94% |
| 2015 | $-6.59M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,498.51% |
US
|
|
| $-3.09B | 718.44% |
US
|
|
| $-4.02B | 964.80% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -617.17% |
NL
|
